Biogen (BIIB) Akcija Цена
Biogen Цена
Prihod je rastao 7,1 % godišnje u poslednjih 19 godina na 9,89 Млрд USD. Zarada po akciji rasla je 14,9 % godišnje u poslednjih 19 godina. neto marža kompanije Biogen sada iznosi 13,1 %, pala sa 14,2 % pre nekoliko godina. Medijana analitičke ciljane cene je 240,00 USD, odnosno iznad trenutnu cenu za 1,7 %. Od 43 analitičara 30 preporučuje kupovinu — ukupni konsenzus je Kupi.
Cena akcije Biogen
Pristupite ovim podacima preko Eulerpool API-ja
100.000 zahteva/mes. besplatno · bez kartice
Biogen poslovni model i analiza akcije
Često postavljana pitanja o akciji Biogen
Biogen Inc.'s business model revolves around the development, manufacturing, and commercialization of therapies for neurological, autoimmune, and rare diseases. As a leading biotechnology company, Biogen focuses on creating innovative treatments to address unmet medical needs. With a diverse portfolio encompassing multiple therapeutic areas, including multiple sclerosis, spinal muscular atrophy, and Alzheimer's disease, Biogen strives to improve patients' lives worldwide. Through strategic collaborations and scientific advancements, the company continues to invest in cutting-edge research and development to bring transformative therapies to patients, making Biogen a key player in the biopharmaceutical industry.
Biogen Inc is primarily active in the biotechnology and pharmaceutical industries.
The main competitors of Biogen Inc in the market are Amgen Inc, AbbVie Inc, and Gilead Sciences Inc.
Biogen Inc is a renowned biotechnology company with a rich history and impressive background. Founded in 1978, Biogen has consistently aimed to develop innovative therapies for patients facing serious neurological and neurodegenerative diseases. Over the years, the company has made significant contributions to the field of biotechnology, especially in areas like multiple sclerosis (MS) and spinal muscular atrophy (SMA). Biogen's mission involves relentless pursuit of scientific excellence and commitment to improving patients' lives. With a diverse portfolio of groundbreaking therapies and a global presence, Biogen continues to be a leading player in the biotechnology industry, dedicated to transforming the course of human health.
Biogen Inc, a leading biotechnology company, has achieved several significant milestones. Notably, the company successfully introduced the first treatment for multiple sclerosis, revolutionizing the lives of patients worldwide. Biogen also developed ground-breaking therapies for spinal muscular atrophy, empowering patients with this rare genetic disease. Moreover, the company made strides in neurology and introduced medications addressing Alzheimer's disease and Parkinson's disease. Biogen's commitment to innovation has led to these remarkable achievements, positioning the company as a pioneer in the biotech industry. As an influential player, Biogen Inc continues to drive advancements in healthcare, improving the quality of life for countless individuals.
Biogen Inc operates in several countries and regions around the world. As a leading biotechnology company, Biogen Inc has a significant presence in the United States, where it is headquartered. Additionally, Biogen Inc has operations and presence in Europe, including countries such as Germany, France, Italy, and Switzerland. The company also serves markets in Asia, with a presence in Japan, South Korea, and several other countries in the region. Biogen Inc's global footprint allows it to reach a wide range of patients and healthcare providers, ensuring its innovative therapies and treatments are accessible to individuals in various parts of the world.
Biogen Inc is a biotechnology company known for its commitment to scientific innovation and improving patients' lives. Guided by their corporate philosophy, Biogen Inc strives to discover, develop, and deliver innovative therapies for neurological, autoimmune, and rare diseases. The company values integrity, diversity, and inclusion in their pursuit of breakthrough treatments, always putting patients at the forefront. Biogen Inc's collaborative approach, dedication to scientific rigor, and passion for making a difference have earned it a leading position in the biotech industry. With a focus on transformative therapies, Biogen Inc continues to drive advancements in healthcare and empower patients worldwide.
Analitičari trenutno postavljaju prosečnu ciljanu cenu 238,69 USD za akciju Biogen (medijana: 240,00 USD), što znači +1,1 % u odnosu na poslednju cenu. Konsenzus se zasniva na 43 ocena.
43 analitičara trenutno ocenjuje akciju Biogen: 30 preporučuje kupovinu, 12 držanje i 1 prodaju. Za 2026 analitičari očekuju da Biogen ostvari prihod 10,45 Млрд USD i zaradu po akciji 12,42 USD.
Po trenutnom kursu akcija Biogen kotira 209,95 EUR (236,00 USD).
Akcija Biogen (BIIB) kotira na 11 berze, uključujući: NASDAQ (BIIB), London (0R1B.L), SIX (Zürich) (BIIB.SW), XETRA (IDP.DE), Frankfurt (IDP.F), München (IDP.MU), Düsseldorf (IDP.DU), Hamburg (IDP.HM).
Biogen Inc. is a biopharmaceutical company specializing in the research, development, and marketing of therapies for neurological, hematological, and autoimmune diseases. It was founded in 1978 and is headquartered in Cambridge, Massachusetts. Biogen currently has three main business segments: Neurology, Hematology, and Biosimilars. The Neurology division focuses on the development and marketing of drugs for the treatment of Multiple Sclerosis (MS), Amyotrophic Lateral Sclerosis (ALS), Spinal Muscular Atrophy (SMA), and other neurological disorders. The Hematology division focuses on the development of therapies for blood diseases such as Hemophilia and Sickle Cell Anemia. The Biosimilars division focuses on the development of generic versions of biological drugs. Biogen has partnerships with other major companies such as Eisai Co. and Ionis Pharmaceuticals to work on the development of new drugs and therapies. The company's business model is based on the sale of patented drugs and the development of new therapies. In summary, Biogen is a biopharmaceutical company specializing in the development and marketing of therapies for neurological, hematological, and autoimmune diseases, aiming to improve the lives of patients worldwide.
očekivana prihod od Biogen je 10,45 Млрд USD. Ova cifra je zasnovana na trenutnim finansijskim podacima i odražava poslovne rezultate preduzeća.
očekivana dobit od Biogen je 1,83 Млрд USD. Neto dobit pokazuje profitabilnost preduzeća nakon odbitka svih troškova.
Odnos cene i zarade (KGV) za Biogen je trenutno 19,00. KGV poredi sadašnju cenu akcije sa zaradom po akciji i pomaže investitorima da procene valuaciju akcije Biogen.
Odnos cene i prihoda (KUV) za Biogen je trenutno 3,32. KUV poredi tržišnu kapitalizaciju sa godišnjim prihodima i služi kao metrika valuacije za akciju Biogen.
Eulpool score kvaliteta za Biogen je 3/10.
ISIN za Biogen je US09062X1037. ISIN (International Securities Identification Number) je globalno jedinstveni identifikator za hartije od vrednosti.
WKN za Biogen je 789617. WKN (Wertpapierkennnummer) je šestocifreni nemački broj za identifikaciju hartija od vrednosti.
Ticker za Biogen je BIIB. Simbol tikera se koristi za trgovinu akcijama Biogen na berzanskom tržištu.
Biogen акција
Biogen Тикер
Biogen FIGI
Sve ključne metrke i detaljne analize Biogen u dubinskoj analizi
Naša analiza akcija za akciju Biogen uključuje važne finansijske pokazatelje kao što su prihod, profit, P/E odnos, P/S odnos, EBIT, kao i informacije o dividendama. Takođe, razmatramo aspekte poput akcija, tržišne kapitalizacije, dugova, kapitala i obaveza kompanije Biogen. Ako tražite detaljnije informacije o ovim temama, na našim podstranicama vam nudimo opsežne analize: